英国药品和健康产品管理局已批准Resmetirom（商品名Rezdiffra）用于治疗成人代谢功能障碍相关脂肪性肝炎。这一决定为MASH患者提供了一种新的治疗选择。该药物的获批基于其临床试验中展现出的疗效与安全性数据。MASH是一种严重的肝脏疾病，与代谢功能障碍密切相关，可导致肝纤维化、肝硬化甚至肝癌。新疗法的问世，有望满足该领域长期存在的未满足医疗需求，改善患者临床结局。
英国药品和健康产品管理局已批准Resmetirom（商品名Rezdiffra）用于治疗成人代谢功能障碍相关脂肪性肝炎。这一决定为MASH患者提供了一种新的治疗选择。该药物的获批基于其临床试验中展现出的疗效与安全性数据。MASH是一种严重的肝脏疾病，与代谢功能障碍密切相关，可导致肝纤维化、肝硬化甚至肝癌。新疗法的问世，有望满足该领域长期存在的未满足医疗需求，改善患者临床结局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.